Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Disease Areas
  • Other Medical News
  • Podcast
  • Videos
  • Education
  • About
    • Vacancies

Tag: Diffuse Large B Cell Lymphoma

Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Presented By
Prof. Won-Seog Kim, Samsung Medical Center, South Korea
Trial
Phase 2, ELM-2 trial
Conference
ASH 2022

20 February, 2023 12:30

Axi-cel improved event-free survival in R/R DLBCL

Presented By
Dr Frederick Locke, Moffitt Cancer Cancer, FL, USA
Trial
Phase 3, ZUMA-7
Conference
ASH 2021

4 February, 2022 11:09

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert
Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA
Trial
Cohort study, RE-MIND2
Conference
ASH 2021

4 February, 2022 11:08

Axi-cel more effective but tisa-cel less toxic in DLBCL

Presented By
Dr Emmanuel Bachy, Hospices Civils de Lyon, France
Conference
ASH 2021

4 February, 2022 11:01

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By
Prof. Hervé Tilly, University of Rouen, France
Trial
Phase 3, POLARIX
Conference
ASH 2021

4 February, 2022 10:56

CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL

Expert
Dr Geoffrey Shouse, City of Hope Comprehensive Cancer Center, USA
Conference
ASH 2021

4 February, 2022 10:20

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Expert
Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA
Trial
Phase 3, BELINDA
Conference
ASH 2021

4 February, 2022 10:03

Mutational analyses are predictive in malignant lymphomas

Presented By
Dr Ismael Fernández-Miranda, Institute of Sanitary Investigation Puerta de Hierro, Spain & Dr Shan-Shan Li, Hospital of Sun Yat-sen University, China
Conference
ESMO 2021

19 November, 2021 09:19

Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma

Presented By
Dr Laurie Sehn, University of British Columbia, Vancouver, Canada
Trial
Phase 3, ESCALADE
Journal
Physician's Weekly
Conference
ASCO 2021

6 August, 2021 12:36

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By
Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA
Conference
EHA 2021

5 August, 2021 11:55

Promising chemo-free treatment options in r/r DLBCL

Presented By
Prof. Marco Ladetto, University del Piemonte Orientale, Italy
Trial
LOTIS-2
Conference
EHA 2021

5 August, 2021 11:17

Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma

Presented By
Dr Roberta Di Blasi, Hospital Saint-Louis, France
Trial
JULIET and ZUMA1
Conference
EHA 2019

9 August, 2019 19:55

Obinutuzumab/polatuzumab in follicular lymphoma

Presented By
Prof. Wojciech Jurczak, Jagiellonian University, Poland
Conference
EHA 2019

9 August, 2019 17:13
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy